SAN-300

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSAN-300
Drug Alias NameAnti-VLA-1-mAbAnti-VLA-1-antibody-SalixSAN-300
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha1/beta1 antagonists
TargetsIntegrin alpha1/beta1
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiogen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBausch Health Americas Inc
Active IndicationsN/A
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A